Development of a Normative Database for Rheumatoid Arthritis (RA) Imaging With Tc99m Tilmanocept

Rheumatoid Arthritis Clinical Trial

Official title:

Development of a Normative Database for Rheumatoid Arthritis (RA) Imaging With Tc99m Tilmanocept

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04947137
• Other study ID #: NAV3-35
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: May 12, 2021
• Est. completion date: April 2022

Study information

• Verified date: March 2022
• Source: Navidea Biopharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will establish a normative database of Tilmanocept Uptake Values (TUVjoint) in healthy controls age-matched to the RA population.

Description:

This is a prospective, open-label, multicenter, single-dose study designed to develop a normative database of TUVjoint in HCs and to assess the feasibility of qualitative and quantitative SPECT/CT assessments in HCs and subjects with active RA.

This study is stratified into 2 arms. Arm 1 is comprised of HCs and Arm 2 is comprised of HCs and clinically diagnosed RA subjects on stable treatment.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 135
• Est. completion date: April 2022
• Est. primary completion date: January 21, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

ALL SUBJECTS

1. The subject has provided written informed consent with HIPAA (Health Information Portability and Accountability Act) authorization before the initiation of any study-related procedures.

2. The subject has agreed to not engage in any diet, lifestyle, or medication changes until study completion.

HEALTHY CONTROL SUBJECTS

3. The subject is 30 years of age or greater at the time of consent.

4. The subject is deemed to be clinically free of any inflammatory disease(s), autoimmune disease(s), or arthropathies and has not experienced joint pain for at least 28 days prior to the consent date.

5. The subject is not currently on anti-inflammatory drugs (including non-steroidal anti-inflammatory drugs [NSAIDs]) and has not taken any anti-inflammatories for at least 28 days prior to the consent date.

6. For all ongoing concomitant medications, the subject has maintained a stable dose for at least 28 days prior to the consent date.

CLINICALLY DIAGNOSED ACTIVE RA SUBJECTS

3. The subject is at least 18 years of age and was = 18 years of age at the time of RA diagnosis.

4. The subject has moderate to severe RA as determined by the 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Classification Criteria (score of = 6/10).

5. The subject has a 28-joint disease activity score (DAS28) of = 3.2 (includes the Erythrocyte Sedimentation Rate [ESR] test and Visual Analog Scale [VAS]).

6. Subjects receiving traditional DMARDs must have been on therapy for = 90 days and at a stable dose for = 30 days prior to the imaging visit (Day 0). 7. If the subject is receiving bDMARD or janus kinase (JAK) inhibitor therapy, they have been at a stable dose > 60 days prior to the imaging visit (Day 0). 8. If the subject is receiving NSAIDs or oral corticosteroids, the dose has been stable for = 28 days prior to the imaging visit (Day 0). The corticosteroid dose must be = 10 mg/day of prednisone or an equivalent steroid dose.

Exclusion Criteria:

1. The subject is pregnant or lactating.

2. The subject size or weight is not compatible with imaging per the investigator.

3. The subject is currently receiving radiation therapy or chemotherapy or has received radiation therapy or chemotherapy in the past six months.

4. The subject has had a finger, hand, and/or wrist amputation or hand or wrist joint arthroplasty.

5. The subject has renal insufficiency as demonstrated by a glomerular filtration rate of < 60 mL/min.

6. The subject has hepatic insufficiency as demonstrated by ALT (alanine aminotransferase [SGPT]) or AST (aspartate aminotransferase [SGOT]) greater than 2 times the upper limit of normal.

7. The subject has any severe, acute, or chronic medical conditions and/or psychiatric conditions and/or laboratory abnormalities that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration that would deem the subject inappropriate for study participation or compromise the safety of the subject or the quality of the data.

8. The subject has any unstable medical illnesses, including hepatic, renal, gastroenterologic, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic disease.

9. The subject has a known allergy to or has had an adverse reaction to dextran exposure.

10. The subject has received an investigational product within 30 days prior to Tc 99m tilmanocept administration (Day 0).

11. The subject has received intra-articular corticosteroid injections = 8 weeks prior to Tc 99m tilmanocept administration (Day 0).

12. The subject has received any radiopharmaceutical within 7 days or 10 half-lives prior to Tc 99m tilmanocept administration (Day 0).

13. Healthy Controls only: The subject has a positive rheumatoid factor and an elevated ESR or CRP.

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• Rheumatoid Arthritis

Intervention

Drug:
• Tc99m tilmanocept
Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.

Locations

Country	Name	City	State
United States	Altoona Center for Clinical Research	Duncansville	Pennsylvania
United States	Kettering Medical Center	Kettering	Ohio
United States	San Marcus Research Clinic	Miami Lakes	Florida
United States	Innovation Medical Research Center	Palmetto Bay	Florida
United States	Sun Research Institute	San Antonio	Texas
United States	Essential Medical Research	Tulsa	Oklahoma
United States	Tranquility Research	Webster	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Navidea Biopharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Normal Limits of TUVjoint in Healthy Subjects	The normal limits of TUVjoint (on a per joint basis) in HC subjects, which are defined as the 5 and 95 percentiles of TUVjoint of bilateral joints (i.e., bilateral wrists, metacarpophalangeal joint [MCPs], proximal interphalangeal [PIPs]).	Up to 39 days
Primary	Qualitative Evaluation of SPECT/CT for Tilmanocept Localization	Presence/absence of tilmanocept localization in the hands and wrists will be summarized with frequency counts and percentages by reader and joint.	Up to 39 days
Secondary	Normal Distribution of TUVjoint	Applicability of the Normal (Gaussian) distribution to TUVjoint data as assessed by normal quantile plots provided per joint and reader and p-value for the Shapiro-Wilk test of Normality.	Up to 39 days
Secondary	Quantitative Evaluation of SPECT/CT	Determination of joint-specific standardized uptake value (SUV) from SPECT/CT imaging within synovial spaces of the bilateral hands and wrists in HCs and RA subjects.	Up to 39 days
Secondary	Planar and SPECT/CT Comparison	Assessment of the predictive value of planar scans for SPECT/CT scans.	Up to 39 days